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1005A-219 Bivalirudin Reduces Hemorrhagic Complications and 
Glycoprotein IlBllllA Inhibitor Usage in Coronary 
Intervention: Results From the NYU Bivalirudin Registry 
Country (Province) 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Michael J. Attubato, Lindsay Friedman, Andrew P. Zinn, Ivan R. Pena-Sing, Robert J. 
Canada (Alberta) 0.5 0.9 1.5 2.1 2.3 3.3 4.9 6.0 8.6 Schanzer, Anthony J. Messina. Stephen Mezzafonte, Howard E. Wirier, Frederick Feit, 
Canada (Ontario) NA NA 0.4 0.6 0.7 0.5 0.7 0.9 1.1 
Canada (Quebec) 0.4 0.5 0.9 1.0 1.4 2.1 2.5 3.3 4.1 
Denmark 0 0 0.1 0.1 0.2 0.6 1.2 1.8 3.4 
England 0.1 0.1 NA NA 0.1 1.3 0.4 0.3 0.3 
Sweden 0.1 0.2 0.3 1 .o 1.4 2.8 4.0 4.5 NA 
U.S. NA 5.2 6.1 7.4 9.0 10.4 11.6 NA NA 
NA=Data not available 
1005A-217 Primary Use of the Cutting Balloon Results in Fewer 
Major Adverse Cardiovascular Events at Six Months 
Than Balloon Angioplasty in a Subgroup of Patients 
With OstiallBifurcation or Small Vessel Lesions 
Tami L. Bair, Joseph B. Muhlestein. Benjamin D. Home, Robert R. Pearson, Clunyu LI, 
Jeffrey L. Anderson, Donald L. LappB. LDS Hospital, Salt Lake City, UT, University of 
Utah, Salt Lake City, UT 
Background: The Cutting Balloon (CB) (Interventional Technologies lnc) incorporates 3 
lo 4 microsurgical blades that produce sharp incisions during dilation, reduclng tearing 
injuries lo the lumen of the target vessel. In randomized trials of type A and B lesions, 
acute and long-term outcomes of CB have not been superior to plain old balloon angio- 
plasty (POBA). However, whether the use of CB can produce results superior to POBA in 
more complicated cases such as ostialibifurcation lesions or in small vessels with post- 
procedure (PP) diameters2.5 mm, remains to be seen. 
Methods: From 1996-2002, in a single institution, 1,580 consecutive patients underwent 
percutaneous coronary intervention for ostialibifurcation lesions or lesions in small ves- 
sels. POBA was utilized as initial therapy in 1,502 and CB in 78 cases. Baseline clinical, 
angiographic. and procedural data were collected and all patients were followed to six 
months for incidence of target vessel revascularization (TVR) and major adverse cardio- 
vascular events (MACE) including death, myocardial infarction and TVR. 
Results: Over-all patient characteristics, including age = 64*12 years, male = 68%. dia- 
betes = 19%. presentation with acute coronary syndrome = 60% did not differ between 
patients receiving POBA or CB. PP vessel diameter was 2.4ti.4 mm for POBA and 
2.720.6 mm for CB (p.zO.001). Adjunctive use of stents was 35% in the POBA group and 
28% in the CB group (p=O.19, OR=O.72). No perforations occurred in either group. TVR 
occurred in 8.1% of POBA and 3.9% of CB (p=O.2O,OR=0.46). MACE occurred in 18.6% 
of POBA and 7.7% of CB (p=O.OO7,OR=0.37). 
Conclusion: Although previous clinical trials involving straightforward type A and B 
lesions have not demonstrated clinical superiority of CB over POBA, in this study of 
select subgroups with ostiaVbifurcation lesions or small vessels, use of CB was associ- 
ated with a significantly lower MACE rate and a clinical trend towards reduced NR. A 
cllnical trend towards reduction in the use of adjundive stenting was also noted with the 
use of CB. 
New York University School of Medicine, New York, NY 
Background: The majority of pts undergoing percutaneous coronary intervention (PCI) 
in the US receive heparin and a GP Ilb/llla inhibitor. In large-scale clinical tnals, the hem- 
orrhagic complication rate (TIMI major + minor hemorrhage) with this regimen has been 
3.5%. We assessed the hypothesis that replacing heparin with bivalirudin would result in 
a low incidence of hemorrhagic and ischemic complications and reduced usage of GP 
Ilb/llla inhibitors. Methods: In 307 pts undergoing PCI, bivalirudin was given as a 0.75 
mg/kg bolus and a 1.75 mglkg infusion during the procedure. Pretreatment with clopi- 
dogrel was encouraged. Two post-PC1 CK-MB measurements were analyzed in all pts 
except those with acute myocardial infarction. Results: The mean age of the pts was 
65?;12 yrs. Multivessel PCI was done in 13%; 1.3 IesionsIpt were treated. Stents were 
implanted in 81% of lewns and 10% of the interventions were in saphenous vein grafts. 
The mean maximum procedural ACT was 38190 sets. Femoral artery closure devices 
were used in 221 (72%) pts. In-hospital events are shown in the table. Conclusion: In 
our single center registry, the substitution of bivalirudin for heparin resulted in a low rate 
of adverse events and low GP Ilb/llia usage. Hemorrhagic complications were decreased 
compared to event rates from previously published trials in pts receiving heparin alone or 
heparin in combination with a GPllb/llla inhibitor. The regimen of bivalirudin and pre-PC1 
clopidogrel therapy IS being tested in the REPLACE-2 Trial. 
In-Hospital Results (n=307) 
n w 
TIMI Major Hemorrhage 0 
TIMI Minor Hemorrhage 2 (0.6) 
Blood Transfusion 0 
Retroperitoneal Bld, Pseudoaneurysm 0 
Death 1 (0.3) 
Q-wave MI 1 (0.3) 
NR - UrgenVAny 1 (0.3) / 3 (0.9) 
MACE 4 (1.2) 
CK-MB > 3x Normal (n=278) 28 (10.0) 
GP llbillla Usage 31 (10.0) 
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Alice Ohanessian, Christophe Caussin, Bernard Lancelin, Pascal Piquet, Sylvie Doubine, 
Hbpital Marie-Lannelongue, Le Plessis Robinson, France 
Background - Recent reports have advocated the use of very low dose unfractionated 
heparin (UFH) (2500 to 5000 IU) among patients undergoing percutaneous coronary 
intervention (PCI). The optimal activated clotting time (ACT) arbitrary recommended for 
PCI is between 300 and 350 s, rarely attalned with low doses of UFH. The purpose of this 
study was to evaluate anticoagulation ranges for low-dose UFH regimens during PCI, 
monitoring APTT. anti-Xa activity and ACT. 
Methods- We prospectively included 250 patients who underwent an ad hoc PCI receiv- 
ing 3000 (n=185) or 4000 (n=65) UFH units. Patients pre-treated by UFH or low weight 
molecular heparin were excluded from the study. At the end of the procedure, ACT 
(Hemochron 401, ITC), APTT and anti-Xa activity (Behring Coagulation Timer) ware 
assayed for each patient arterial blood sample. A good anticoagulation level was defined 
by an anti-Xa activity > 0.4 IUlml and APTT ratio x.5. Creatine kinase (CK) was system- 
atically assayed 8 to 12 hours after PCI (N<150 U/I). periprocedural Ml was defined by 
CK>450. A clinical evaluation was performed at 7 and 30 days. 
Results - age was 63.1 *I 3 years. Weight:76.7+11.7 Kg. Current smokers: 31%, diabe- 
tes: 20%, hypertension: 49.7%, dyslipidemia: 66%. Prior PCI: 48%, prior CABG: 11.5%, 
prior Ml: 34%. Acute coronary syndrome: 65%. Mean heparin dose: 3274 * 459 IU. ACC/ 
AHA classification: A:19.5%, B1:35.9%, B2:32.3%, C: 12.3%. Stenting: 84%, primary 
stenting: 76%. Biological results: ACT: 187i36 s. anti-Xa 0.77eO.3 IU/ml, APTT>120s: 
94%. CK:61t59U/l. Rate of complications: false aneurysm:l%, minor groin 
hematoma:3%. urgent revascularisation:l patient, Ml 0%. death 0%. No MACE at 7 and 
30 days. 
Conclusion - PCI with very low dose UFH (3000 to 4000 IU) appeared to be safe. Anti- 
Xa activity was within therapeutical ranges and APT ratio was > in 94% of the cases 
despite low mean ACT of 187. These findings may explain the safety of PCI with low 
dose heparin. 
1006-l 78 Three-Dimensional Intravascular Ultrasound 
Assessment After the Implantation of Estrogen-Eluting 
PC-Coated Stents in Human Coronary Arteries 
Marco A. Costa, Jose Eduardo M. Sousa, Alexandre A. Abizaid, Andrea S. Abizaid. 
Rodolfo Staico, Luiz A. Mattes, Fausto Feres, lbraim Pinto, Theodore A. Bass, Amanda 
Sousa, EASTER Study Group, University of Florida, Jacksonville, FL, Institute Dante 
Pauanese of Cardiology, Sao Paula, Brazil 
Background Side-effects of anti-proliferative drugs pose limitations lo drug-eluting 
stents. Estrogen inhibited proliferation of smooth muscle cells in animals. Estrogen also 
accelerated endothelial cell growth. We used SD-intravascular ultrasound (IVUS) lo 
determine the human vascular response following the implantation of PC coated stents 
loaded with la-estradiol. 
Methods Thirty patients with de novo coronary disease were treated with the implanta- 
tion of a single 17P-estradiol eluting stent. Clopidogrel was discontinued 28 days post 
stent implantation. IVUS were obtained using a motorized pullback device post-proce- 
dure and at 6 months. Image reconstruction and volumetric analyses were performed by 
an independent core laboratory et the University of Florida, Jacksonville. Measurements 
were performed for the stent and edges segments (5mm proximal and distal). Presence 
of stent malapposition and echolucent intimal tissue (black hole) were determined. 
Results All vessels were patent at 6 months. One patient had repeat revascularization. 
There were no thrombus or black hole images detected by IVUS. There were no late 
Sti?nt malapposition or aneurysm. Percent intimal hyperplasia was only 23.4+-11.9% of 
the stent volume. 
Conclusion This first human experience demonstrates the potential of 17bestradiol 
eluting stems lo prevent neointimal proliferation, without the associated risk of stem 
thrombosis or pathological vascular response. 
